Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies

Antzeko izenburuak

• Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
  nork: Anderson, Michael S, et al.
  Argitaratua: (2017)
• Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study
  nork: Layton, A.M., et al.
  Argitaratua: (2015)
• The role of brimonidine tartrate gel in the treatment of rosacea
  nork: Jackson, J Mark, et al.
  Argitaratua: (2015)
• The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea
  nork: Johnson, Andrew William, et al.
  Argitaratua: (2015)
• Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies
  nork: Fowler, J., et al.
  Argitaratua: (2012)